How Drug Cos. Can Adapt To New Reference Pricing Rules

The final days of the Trump administration were marked by the publication of a flurry of drug pricing regulations, among the most controversial of which was a regulation that would have purported to test a new most-favored-nations reimbursement mechanism for the top 50 physician-administered prescription medicines paid for under Medicare Part B.